Cargando…

Does FFAR4 Agonism have Therapeutic Potential in Cardiometabolic Disease?

Detalles Bibliográficos
Autor principal:	Lay, Abigail C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8354430/ https://www.ncbi.nlm.nih.gov/pubmed/34282845 http://dx.doi.org/10.1210/endocr/bqab145

Ejemplares similares

Beta-2 Agonism: A Potential Therapeutic Target for Dyslipidemia
por: Davidson, Michael H.
Publicado: (2015)

Expression of FFAR3 and FFAR4 Is Increased in Gastroesophageal Reflux Disease
por: Fabisiak, Adam, et al.
Publicado: (2020)

Anti-Atherosclerotic Potential of Free Fatty Acid Receptor 4 (FFAR4)
por: Kiepura, Anna, et al.
Publicado: (2021)

Optimization of First-in-Class Dual-Acting FFAR1/FFAR4 Allosteric Modulators with Novel Mode of Action
por: Lückmann, Michael, et al.
Publicado: (2022)

Omega-3 Fatty Acids and FFAR4
por: Oh, Da Young, et al.
Publicado: (2014)

“Let's Stay Together”; GIP and GLP-1 dual agonism in the treatment of metabolic disease
por: DiMarchi, Richard D.
Publicado: (2018)

D2/D3 Receptor Agonism: Paving the Way for a New Therapeutic Target for Taste Disorders in Parkinson’s Disease and Other Conditions?
por: Mantovani, Elisa, et al.
Publicado: (2022)

Defective Wnt Signaling: A Potential Contributor to Cardiometabolic Disease?
por: Arnold, Amy C., et al.
Publicado: (2015)

The therapeutic potential of GLP‐1 receptor biased agonism
por: Jones, Ben
Publicado: (2021)

Prostaglandin I(2) Receptor Agonism for Proteinuria and Diabetes: Good for the Goose and Good for the Gander?
por: Menon, Madhav C., et al.
Publicado: (2016)

FFAR2-FFAR3 receptor heteromerization modulates short-chain fatty acid sensing
por: Ang, Zhiwei, et al.
Publicado: (2018)

Molecular characterization of free fatty acid receptors FFAR2 and FFAR3 in the domestic cat
por: Yamamoto, Ichiro, et al.
Publicado: (2020)

Lipid-Sensing Receptor FFAR4 Modulates Pulmonary Epithelial Homeostasis following Immunogenic Exposures Independently of the FFAR4 Ligand Docosahexaenoic Acid (DHA)
por: Sveiven, Stefanie N., et al.
Publicado: (2023)

The brain strikes back: Hypothalamic targets for peripheral CB(1) receptor inverse agonism
por: Cota, Daniela
Publicado: (2017)

Inverse agonism and its therapeutic significance
por: Khilnani, Gurudas, et al.
Publicado: (2011)

Free Fatty Acid Receptors (FFARs) in Adipose: Physiological Role and Therapeutic Outlook
por: Al Mahri, Saeed, et al.
Publicado: (2022)

Cardiovascular surrogate markers and cardiometabolic therapeutics: a viewpoint learned from clinical trials on dipeptidyl peptidase-4 inhibitors
por: Tanaka, Atsushi, et al.
Publicado: (2021)

CD40 agonism improves anti-tumor T cell priming induced by the combination of radiation therapy plus CTLA4 inhibition and enhances tumor response
por: Charpentier, Maud, et al.
Publicado: (2023)

Mechanistic Studies on the Stereoselectivity of FFAR1 Modulators
por: Teng, Dan, et al.
Publicado: (2022)

Harnessing MerTK agonism for targeted therapeutics
por: Kedage, Vivekananda, et al.
Publicado: (2019)

Nerve growth factor: Does this have the potential to become a miraculous treatment for diabetic heart?
por: Naruse, Keiko
Publicado: (2012)

Molecular mechanism of agonism and inverse agonism in ghrelin receptor
por: Qin, Jiao, et al.
Publicado: (2022)

Complement C3: an emerging risk factor in cardiometabolic disease
por: Hertle, E., et al.
Publicado: (2012)

Lack of FFAR1/GPR40 Does Not Protect Mice From High-Fat Diet–Induced Metabolic Disease
por: Lan, Hong, et al.
Publicado: (2008)

Molecular mechanism of fatty acid activation of FFAR1
por: Kumari, Punita, et al.
Publicado: (2023)

Effect of short chain fatty acids on the expression of free fatty acid receptor 2 (Ffar2), Ffar3 and early-stage adipogenesis
por: Frost, G, et al.
Publicado: (2014)

Biased agonism
por: Kenakin, Terry
Publicado: (2009)

Agonizing Hedgehog
por: Weitzman, Jonathan B
Publicado: (2002)

Agon : ballet for twelve dancers
por: Stravinsky, Igor, 1882-1971
Publicado: (1957)

EPA Prevents the Development of Abdominal Aortic Aneurysms through Gpr-120/Ffar-4
por: Kamata, Ryo, et al.
Publicado: (2016)

Does artificial intelligence have a role in the IVF clinic?
por: Chow, Darren J X, et al.
Publicado: (2021)

Does having more sustainable communities bring better sustainability?
por: Zhang, Junze, et al.
Publicado: (2022)

Variants in the FFAR1 Gene Are Associated with Beta Cell Function
por: Kalis, Martins, et al.
Publicado: (2007)

Ffar2 expression regulates leukaemic cell growth in vivo
por: Bindels, Laure B, et al.
Publicado: (2017)

Human and mouse monocytes display distinct signalling and cytokine profiles upon stimulation with FFAR2/FFAR3 short-chain fatty acid receptor agonists
por: Ang, Zhiwei, et al.
Publicado: (2016)

Does group A strep have any skin in the ARF game?
por: Tyrrell, Gregory J.
Publicado: (2021)

Optimal Evaluation of Suspected Choledocholithiasis: Does This Patient Really Have Choledocholithiasis?
por: Lee, Tae Yoon
Publicado: (2017)

Does glucagon have a positive inotropic effect in the human heart?
por: Hernández-Cascales, Jesus
Publicado: (2018)

Upregulated expression of FFAR2 and SOC3 genes is associated with gout
por: Orji, Oliver C, et al.
Publicado: (2022)

Aberrant fatty acid profile and FFAR4 signaling confer endocrine resistance in breast cancer
por: Chu, Xiao, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_5if4rlnkqac4j4h9e8p6oiu16v